Ultralife Corp (ULBI) · Oct 28, 2026 · Acquisition
$320M acquisition — $16.00 cash per share; ~$320M enterprise value; 166% premium
Ultralife’s acquisition by EnerSys delivers a $16-per-share cash offer and shifts the company from standalone growth to a strategic sale.
Ultralife is a battery and communications supplier trying to turn improving margins, backlog and defense demand into profitable growth. Its latest reported quarter showed sales of $47.9 million, adjusted EBITDA of $6.1 million and backlog of $117.5 million, after a weaker first quarter and uneven commercial demand.
The standalone story is being replaced by a strategic exit. EnerSys will acquire Ultralife through a tender offer followed by a merger for $16 per share in cash, valuing the transaction at approximately $320 million including assumed net debt. The offer represents a 166% premium to Ultralife’s October 26 closing price. 〔0〕
| Deal term | Filing detail |
|---|---|
| Cash offer | $16.00 per share |
| Enterprise value | Approximately $320 million |
| Premium | 166% to October 26 closing price |
| Buyer-reported synergies | $15 million–$20 million annual run-rate within 18 months |
| Expected closing | First quarter of calendar year 2027 |
| Stockholder support | Approximately 40.3% of shares |
| Termination fee | $10.3 million |
For Ultralife holders, this is a substantial value crystallization rather than an operating beat. There is no published earnings-style consensus to beat for an acquisition announcement, but the premium is the clearest benchmark: the filing converts a still-developing defense-growth opportunity into a certain cash offer, subject to closing. EnerSys says the combination adds multi-chemistry battery capabilities, specialized manufacturing capacity and exposure to drones, counter-drones, munitions and soldier power. 〔1〕
The buyer’s strategic rationale is credible, but the claimed upside remains prospective. EnerSys expects $15 million to $20 million of annual run-rate cost synergies within the first 18 months and says the deal should become accretive to adjusted diluted EPS within approximately 18 months after closing. Those are buyer estimates, not realized benefits, so the filing changes ownership economics immediately but does not yet prove the integration case.
Closing risk is meaningful but not financing-driven. EnerSys will fund the deal with cash on hand, so there is no financing condition. However, the offer still requires more than 50% of shares to be tendered, regulatory clearances including U.S. HSR and U.K. NSIA review, and other customary conditions. The 40.3% support agreement provides a strong base but is explicitly insufficient by itself to satisfy the minimum tender condition. 〔2〕
Bottom line: This is a major change to Ultralife’s story: the company is moving from an uncertain standalone growth-and-deleveraging path to a $16-per-share cash sale at a 166% premium. The main remaining question is execution through the tender offer and regulatory process, not whether the transaction is strategically material.
Tender offer commencement; closing targeted for Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!